Tesaro Inc., of Waltham, Mass, said the U.K.'s National Institute for Health and Care Excellence (NICE) plans to make the PARP inhibitor Zejula (niraparib) available to women in England and Wales with recurrent platinum-sensitive ovarian cancer via the Cancer Drugs Fund (CDF).